Patient-Reported Outcomes in Market Access Strategy
What are Patient-Reported Outcomes (PROs)?
Patient-reported outcomes (PROs) are information about a patient’s health that comes directly from the patient, without interpretation by a clinician or another person. PROs may capture symptoms such as pain or fatigue, physical and emotional functioning, health-related quality of life, treatment satisfaction, and health behaviors. By complementing clinical data and administrative claims, PROs can provide additional insight into how disease and treatment affect patients’ daily lives.
Why Are PROs Important?
DruPROs can help manufacturers better understand the patient journey, including the symptoms, functional limitations, and treatment burdens that patients find most difficult. For example, patients may value improvements in how a treatment is administered, even when those benefits are not reflected in traditional clinical endpoints or claims data.
When collected through clinical trials or real-world research, PROs can complement clinical and economic evidence by showing the effects of treatment from the patient perspective. They may also help identify unmet needs, inform patient-centered clinical development, and support post-launch monitoring of symptoms, quality of life, and treatment experience.
The value of PRO evidence depends on selecting measures that are appropriate for the patient population, research question, and intended use. The interpretation of PRO findings should take into account the study design, the PRO instrument selected, the timing of assessments, data completeness, and whether the observed changes are clinically meaningful.
How Can PROs Support Market Access Strategy?
Within market access, PROs should be considered one component of the broader evidence package used to support payer, reimbursement, and health technology assessment discussions. As healthcare decision-makers increasingly consider patient-centered evidence alongside clinical and economic outcomes, PROs can strengthen a product’s value proposition when interpreted together with clinical outcomes, real-world evidence, healthcare utilization, and cost data. Although PROs do not independently determine coverage or pricing, they may provide additional evidence on the experiences and outcomes that matter to patients. Potential applications may include:
|
PRO Activity |
Market Access Application |
|---|---|
|
Identify patient needs and priorities |
Address evidence gaps and evaluate patient experience in routine clinical practice |
|
Select PRO endpoints and instruments |
Align clinical development with anticipated payer, HEOR, and HTA evidence needs |
|
Include PRO findings in value dossiers |
Add evidence on quality of life, functioning, symptoms, or treatment burden |
|
Support health economic modeling |
Inform health-state utilities and cost-utility analyses when appropriate |
|
Communicate PRO findings |
Integrate patient-centered evidence into publications, payer materials, and field tools |
|
Generate post-launch PRO evidence |
Address evidence gaps and evaluate patient experience in routine clinical practice |
Key: HEOR, health economics and outcomes research; HTA, health technology assessment.
Planning PRO Evidence Early
PRO strategy is most effective when considered early in product development. Manufacturers should define which market access decisions the evidence is intended to support, which outcomes matter most to patients, and how the findings will be incorporated into the broader clinical, HEOR, and real-world evidence strategy.
Early planning can also help determine whether a generic quality-of-life measure, a disease-specific instrument, or a combination of measures is needed to support clinical development, value demonstration, or economic modeling.
Integrating PROs into a Broader Evidence Strategy
For market access teams, the objective is not simply to collect more PRO data. Rather, it is to generate relevant, credible patient-centered evidence that complements clinical outcomes, healthcare utilization, cost data, and real-world evidence. When thoughtfully integrated into a broader evidence-generation strategy, PROs can help strengthen value demonstration throughout the product lifecycle.
Strengthen Your Patient-Centered Evidence Strategy
Magnolia Market Access can help pharmaceutical manufacturers develop and implement patient-reported outcome strategies that support market access, HEOR, and real-world evidence objectives. Our team can support PRO strategy, instrument evaluation, evidence-gap assessment, and the integration of PRO findings into value dossiers, publications, payer materials, and field tools.
Contact Magnolia Market Access to discuss how PRO evidence can complement your broader market access strategy.
Related Magnolia Market Access Briefs
- How the FDA Uses Patient-Reported Outcomes (PROs)
- What Is a Chart Review?
- What Are Real-World Evidence and Real-World Data?
References
- Centers for Medicare & Medicaid Services. Patient-Reported Outcome Measures (PROMs) Overview. CMS Measures Management System Hub. Accessed July 27, 2026. https://mmshub.cms.gov/about-quality/types/proms/overview
- U.S. Food and Drug Administration. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Published February 2022. Accessed July 27, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients
- U.S. Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Published October 2025. Accessed July 27, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome
- U.S. Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series: Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making. Accessed July 28, 2026. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical
- Rylands AJ, Maruszczyk K, Aiyegbusi OL, et al. Designing and Implementing Real-World Patient-Reported Outcomes—Emerging Recommendations: A Good Practices Report of an ISPOR Task Force. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published 2026. Accessed July 27, 2026. https://www.ispor.org/docs/default-source/ispor-good-practices-for-outcomes-research-index/ispor-designing-and-implementing-real-world-patient-reported-outcomes-rw–pros-tfr.pdf
- Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 5.0. Published April 2024. Accessed July 27, 2026. https://www.amcp.org/format
- Randhawa S, Gater A, Bentley R, et al. Patient-Reported Outcomes Now and Into the Future: Multistakeholder Perspectives on Optimizing the Use of Patient-Reported Outcome Evidence in Decision Making Across the US Healthcare Continuum. Value Health. 2025;28(12):1868-1880. doi:10.1016/j.jval.2025.08.008.